These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 19180263)

  • 1. Oral formulations of budesonide: a novel treatment for inflammatory bowel disease.
    Svoboda RP; Patel DH; Olden KW
    Drugs Today (Barc); 2008 Nov; 44(11):857-63. PubMed ID: 19180263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral pH-modified release budesonide for treatment of inflammatory bowel disease, collagenous and lymphocytic colitis.
    Gross V
    Expert Opin Pharmacother; 2008 May; 9(7):1257-65. PubMed ID: 18422482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review article: Drug development in inflammatory bowel disease: budesonide--a model of targeted therapy.
    Hamedani R; Feldman RD; Feagan BG
    Aliment Pharmacol Ther; 1997 Dec; 11 Suppl 3():98-107; discussion 107-8. PubMed ID: 9467984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preparation of budesonide-loaded polycaprolactone nanobeads by electrospraying for controlled drug release.
    Midhun BT; Shalumon KT; Manzoor K; Jayakumar R; Nair SV; Deepthy M
    J Biomater Sci Polym Ed; 2011; 22(18):2431-44. PubMed ID: 21144167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Budesonide in the treatment of inflammatory bowel disease.
    Silverman J; Otley A
    Expert Rev Clin Immunol; 2011 Jul; 7(4):419-28. PubMed ID: 21790284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low bioavailability steroids in inflammatory bowel disease: an old chestnut or a whole new ballgame?
    Saibeni S; Meucci G; Papi C; Manes G; Fascì-Spurio F
    Expert Rev Gastroenterol Hepatol; 2014 Nov; 8(8):949-62. PubMed ID: 24882015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delivery system for budesonide based on lipid-DNA.
    Liu Y; Bos IST; Oenema TA; Meurs H; Maarsingh H; Hirsch AKH
    Eur J Pharm Biopharm; 2018 Sep; 130():123-127. PubMed ID: 29908939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral budesonide for the therapy of post-liver transplant de novo inflammatory bowel disease: a case series and systematic review of the literature.
    Barritt AS; Zacks SL; Rubinas TC; Herfarth HH
    Inflamm Bowel Dis; 2008 Dec; 14(12):1695-700. PubMed ID: 18618676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of budesonide nanocluster dry powder aerosols: processing.
    El-Gendy N; Selvam P; Soni P; Berkland C
    J Pharm Sci; 2012 Sep; 101(9):3425-33. PubMed ID: 22539360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New steroids for IBD: progress report.
    Hanauer SB
    Gut; 2002 Aug; 51(2):182-3. PubMed ID: 12117876
    [No Abstract]   [Full Text] [Related]  

  • 11. [Adverse effect free therapy for inflammatory bowel diseases. Oral steroid with topical effect].
    MMW Fortschr Med; 2003 Sep; 145(38):61. PubMed ID: 14603689
    [No Abstract]   [Full Text] [Related]  

  • 12. Redox-sensitive nanoparticles based on 4-aminothiophenol-carboxymethyl inulin conjugate for budesonide delivery in inflammatory bowel diseases.
    Sun Q; Luan L; Arif M; Li J; Dong QJ; Gao Y; Chi Z; Liu CG
    Carbohydr Polym; 2018 Jun; 189():352-359. PubMed ID: 29580419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hierarchical structured and programmed vehicles deliver drugs locally to inflamed sites of intestine.
    Li W; Li Y; Liu Z; Kerdsakundee N; Zhang M; Zhang F; Liu X; Bauleth-Ramos T; Lian W; Mäkilä E; Kemell M; Ding Y; Sarmento B; Wiwattanapatapee R; Salonen J; Zhang H; Hirvonen JT; Liu D; Deng X; Santos HA
    Biomaterials; 2018 Dec; 185():322-332. PubMed ID: 30267958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Steroids in inflammatory bowel disease].
    López San Román A; Garrido E
    Rev Esp Enferm Dig; 2015 Sep; 107(9):573. PubMed ID: 26334467
    [No Abstract]   [Full Text] [Related]  

  • 15. [Locally acting corticosteroids in inflammatory bowel disease. Are they effective? Are they really less toxic?].
    Nos Mateu P
    Gastroenterol Hepatol; 2008 Sep; 31 Suppl 3():16-21. PubMed ID: 19087859
    [No Abstract]   [Full Text] [Related]  

  • 16. Preparation, in vitro and in vivo evaluation of budesonide loaded core/shell nanofibers as oral colonic drug delivery system.
    Xu Q; Zhang N; Qin W; Liu J; Jia Z; Liu H
    J Nanosci Nanotechnol; 2013 Jan; 13(1):149-56. PubMed ID: 23646710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacokinetic data for different 5-aminosalicylic acid and budesonide preparations].
    Klotz U
    Med Klin (Munich); 1999 Feb; 94 Suppl 1():16-22. PubMed ID: 10194943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral locally active steroids in inflammatory bowel disease.
    Nunes T; Barreiro-de Acosta M; Marin-Jiménez I; Nos P; Sans M
    J Crohns Colitis; 2013 Apr; 7(3):183-91. PubMed ID: 22784947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review article: issues in oral administration of locally acting glucocorticosteroids for treatment of inflammatory bowel disease.
    Friend DR
    Aliment Pharmacol Ther; 1998 Jul; 12(7):591-603. PubMed ID: 9701522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted delivery, safety, and efficacy of oral enteric-coated formulations of budesonide.
    Fedorak RN; Bistritz L
    Adv Drug Deliv Rev; 2005 Jan; 57(2):303-16. PubMed ID: 15555744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.